#kidney

A decade of aging brings on heart and kidney troubles in people with HIV.

“It’s the chance of showing people that I am just as normal as you,” says long-term survivor Nina Martinez.

The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.

Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.

Following a group of Ethiopian children on antiretrovirals, researchers observed declining kidney function but improving liver enzymes.

Transplantees can be treated safely and effectively for hep C, so greater education regarding such methods is in order.

Researchers analyzed health data from 2004 and 2014 regarding a cohort of people with HIV who initially had a median age of 41.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Advocate John Tenorio could be the first HIV-positive person to receive a kidney from a living donor with HIV.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.

Nevertheless, researchers advise careful kidney monitoring when pairing the medications.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.